Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Latest News on AMLX

Feb 14, 2025, 10:00 AM EST - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Feb 13, 2025, 10:00 AM EST - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

Feb 12, 2025, 10:00 AM EST - 10 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

Feb 11, 2025, 10:00 AM EST - 11 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Feb 10, 2025, 10:00 AM EST - 12 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

Feb 10, 2025, 9:00 AM EST - 12 days ago

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 9, 2025, 10:00 AM EST - 13 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

Feb 7, 2025, 10:00 AM EST - 15 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 6, 2025, 10:00 AM EST - 16 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

Feb 4, 2025, 10:00 AM EST - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

Feb 3, 2025, 10:00 AM EST - 19 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

Feb 2, 2025, 10:00 AM EST - 20 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Jan 30, 2025, 11:00 AM EST - 23 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Jan 21, 2025, 9:00 AM EST - 4 weeks ago

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Jan 13, 2025, 10:00 AM EST - 5 weeks ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 10, 2025, 8:26 AM EST - 6 weeks ago

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 9, 2025, 7:30 PM EST - 6 weeks ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 6, 2025, 9:00 AM EST - 6 weeks ago

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Dec 31, 2024, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Dec 4, 2024, 7:30 AM EST - 2 months ago

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Nov 27, 2024, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 2:40 PM EST - 3 months ago

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Nov 9, 2024, 10:06 AM EST - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 17, 2024, 9:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Oct 15, 2024, 9:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Oct 3, 2024, 3:06 PM EDT - 5 months ago

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Aug 28, 2024, 8:30 AM EDT - 6 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 9:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Aug 9, 2024, 9:02 AM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 9:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Aug 2, 2024, 9:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

Jul 10, 2024, 3:32 PM EDT - 8 months ago

Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?

Jul 10, 2024, 2:23 PM EDT - 8 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript

Jul 10, 2024, 7:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

Jul 9, 2024, 4:01 PM EDT - 8 months ago

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Jun 25, 2024, 3:35 PM EDT - 8 months ago

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 21, 2024, 6:07 PM EDT - 8 months ago

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

Jun 4, 2024, 9:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 9, 2024, 10:40 AM EDT - 10 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

May 8, 2024, 9:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

May 2, 2024, 9:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 10, 2024, 9:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Apr 9, 2024, 7:00 AM EDT - 11 months ago

Market Cap	226.21M
Revenue (ttm)	380.79M
Net Income (ttm)	49.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	12.94%
Debt to Equity Ratio	0.00

Volume	492,200
Avg Vol	830,860
Day's Range	N/A - N/A
Shares Out	68.55M
Stochastic %K	3%
Beta	-0.54
Analysts	Sell
Price Target	$7.33